Cargando…
Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
OBJECTIVE: This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). METHODS: The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 7...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059722/ https://www.ncbi.nlm.nih.gov/pubmed/33666270 http://dx.doi.org/10.1002/jcla.23650 |
_version_ | 1783681231707176960 |
---|---|
author | Jiang, Hongyang Zhang, Yan Xu, Dongyan Wang, Qing |
author_facet | Jiang, Hongyang Zhang, Yan Xu, Dongyan Wang, Qing |
author_sort | Jiang, Hongyang |
collection | PubMed |
description | OBJECTIVE: This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). METHODS: The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 76 patients with diabetic nephropathy of type 2 diabetes, a randomized double‐blind and placebo‐controlled clinical trial was conducted to evaluate the administration of 3.2 × 10(9) CFU probiotic supplements per day (Bifidobacterium bifidum, 1.2 × 10(9) CFU, Lactobacillus acidophilus 4.2 × 10(9) CFU, Streptococcus thermophilus 4.3 × 10(9) CFU) for 12 weeks on glycemic control of patients, including fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin (HbA1c), microalbuminuria/creatinine (mAlb/Cr) and estimated glomerular filtration rate (eGFR) levels. The placebo group daily received empty capsules filled with starch. RESULTS: After 12 weeks, the administration of probiotics demonstrated a significant reduction in fasting blood glucose (10.68 ± 3.24 mmol/L before vs. 7.81 ± 2.77 mmol/L after, p < 0.05), HbA1c (8.19 ± 1.60% before vs. 7.32 ± 1.20% after, p < 0.05) and mAlb/Cr (101.60 ± 22.17 mg/g before vs. 67.53 ± 20.11 mg/g after, p < 0.05), while only mAlb/Cr level was significantly lower in the probiotic group than in the placebo group after intervention (67.53 ± 20.11 mg/g vs. 87.71 ± 23.01, p < 0.05). Meanwhile, there was no significant reduction of 2 h postprandial blood glucose level (18.95 ± 5.23 mmol/L vs. 17.35 ± 6.28 mmol/L, p = 0.24) and eGFR (84.34 ± 6.97 ml/min vs. 82.8 ± 8.72 ml/min, p = 0.45) in patients before and after probiotic intake. In addition, the placebo group failed to show any significant change of these parameters. CONCLUSION: This clinical study revealed probiotic administration could ameliorate glycemic control of patients with diabetic nephropathy, potentiating its therapeutic potential in clinical application. |
format | Online Article Text |
id | pubmed-8059722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80597222021-04-23 Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study Jiang, Hongyang Zhang, Yan Xu, Dongyan Wang, Qing J Clin Lab Anal Research Articles OBJECTIVE: This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). METHODS: The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 76 patients with diabetic nephropathy of type 2 diabetes, a randomized double‐blind and placebo‐controlled clinical trial was conducted to evaluate the administration of 3.2 × 10(9) CFU probiotic supplements per day (Bifidobacterium bifidum, 1.2 × 10(9) CFU, Lactobacillus acidophilus 4.2 × 10(9) CFU, Streptococcus thermophilus 4.3 × 10(9) CFU) for 12 weeks on glycemic control of patients, including fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin (HbA1c), microalbuminuria/creatinine (mAlb/Cr) and estimated glomerular filtration rate (eGFR) levels. The placebo group daily received empty capsules filled with starch. RESULTS: After 12 weeks, the administration of probiotics demonstrated a significant reduction in fasting blood glucose (10.68 ± 3.24 mmol/L before vs. 7.81 ± 2.77 mmol/L after, p < 0.05), HbA1c (8.19 ± 1.60% before vs. 7.32 ± 1.20% after, p < 0.05) and mAlb/Cr (101.60 ± 22.17 mg/g before vs. 67.53 ± 20.11 mg/g after, p < 0.05), while only mAlb/Cr level was significantly lower in the probiotic group than in the placebo group after intervention (67.53 ± 20.11 mg/g vs. 87.71 ± 23.01, p < 0.05). Meanwhile, there was no significant reduction of 2 h postprandial blood glucose level (18.95 ± 5.23 mmol/L vs. 17.35 ± 6.28 mmol/L, p = 0.24) and eGFR (84.34 ± 6.97 ml/min vs. 82.8 ± 8.72 ml/min, p = 0.45) in patients before and after probiotic intake. In addition, the placebo group failed to show any significant change of these parameters. CONCLUSION: This clinical study revealed probiotic administration could ameliorate glycemic control of patients with diabetic nephropathy, potentiating its therapeutic potential in clinical application. John Wiley and Sons Inc. 2021-03-05 /pmc/articles/PMC8059722/ /pubmed/33666270 http://dx.doi.org/10.1002/jcla.23650 Text en © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Jiang, Hongyang Zhang, Yan Xu, Dongyan Wang, Qing Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study |
title | Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study |
title_full | Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study |
title_fullStr | Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study |
title_full_unstemmed | Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study |
title_short | Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study |
title_sort | probiotics ameliorates glycemic control of patients with diabetic nephropathy: a randomized clinical study |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059722/ https://www.ncbi.nlm.nih.gov/pubmed/33666270 http://dx.doi.org/10.1002/jcla.23650 |
work_keys_str_mv | AT jianghongyang probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy AT zhangyan probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy AT xudongyan probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy AT wangqing probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy |